|
|
Sarepta Therapeutics Inc.
|
 |
||||||||
|
 |
  |
 |
|
|
||
 |
 |
 
|
return to message board, top of board |
Copied from a thread on twitter that Gary Brode posted Today (Nov. 17, 2022)From Gary Brode twitter @Gary_Brode 1/ - "I spoke with a pharmaceutical manager regarding $SRPT drug for Duchenne (Muscular Dystrophy) through @StreamRG . Here's what I learned: - Sarepta has Roche as a commercialization/distribution partner outside the US. 2/ - Initial expectations for the drug were very high, but subsequent trials have indicated that while worthwhile, the drug isn't as effective as originally hoped. - $PFE has a competing drug that uses as different virus as the genetic carrier. 3/ - PFE had better trial designs early and that allowed them to narrow the gap or possibly take the lead for which drug gets approved first. Possible that SRPT gets approved first in the US and PFE first in Europe. Bad trial design has delayed SRPT. 4/ - Because the two drugs use a different delivery virus, there may be room in the market for both. (This is different from info from prior calls where experts thought only one drug would succeed.) 5/ - He expects SRPT drug to get approval in the US in 2023 and in Europe in 2024. Possible PFE beats SRPT in Europe. Small possibility they beat SRPT to market in the US as well. - He's not sure which drug is better. It's close. 6/ - Expert thinks a second dose may be possible by working with a company that can use a complimentary drug to prevent a negative immune reaction to a second shot. (This is different from info from prior calls where experts said one shot one time) 7/ - If a second shot is possible, he's not sure whether it would be better to add a second dose of the original drug, or to mix/match with the drug not received already. This would take multiple studies and years to determine." |
|
|
return to message board, top of board |
| Msg # | Subject | Author | Recs | Date Posted |
| 14491 | Re: Copied from a thread on twitter that Gary Brode posted Today (Nov. 17, 2022) | schmiggins | 0 | 11/18/2022 6:15:02 PM |
